Jammu, Apr 13: A Memorandum of Understanding (MoU) was signed between the Directorate of AYUSH J&K, National Institute of Ayurveda (Deemed to be University) Jaipur Rajasthan, (Advanced Centre for Treatment, Education and Research for Cancer) ACTREC Tata Memorial Centre, Navi Mumbai and AIMIL Pharmaceuticals India Ltd, at the National Institute of Ayurveda (DU) Jaipur on April 10, 2023, for the development of Anti-Cancer Ayurvedic Formulation (V2S2).
Prof. Sanjeev Sharma Vice-Chancellor NIA (DU) Jaipur (Representing National Institute of Ayurveda), Dr. Anil Kumar Sharma Vice-President AIMIL Pharmaceuticals India Ltd along with other dignitaries attended on physical mode while Dr Jyoti Kode Scientist B ACTREC (Representing TATA ACTREC) and Dr Mohan Singh Director Ayush, J&K (representing Directorate of Ayush, J&K) attended the ceremony on virtual mode.
This prestigious research project for cancer treatment through Ayurveda was initiated by Dr. Sandeep Charak under the guidance of Dr Mohan Singh, Director Ayush J&K/ Dr Rakesh Kumar Raina Assistant Director, Directorate of Ayush J&K and approval of Bhupinder Kumar IAS, Secretary to the Government Health & Medical Education Department for developing coded formulation as a safer and effective treatment in oncological conditions.
Dr. Sandeep Charak from Directorate of Ayush, J&K and Dr. Jyoti Kode from ACTREC, Tata Memorial Cancer Centre Mumbai, have been designated as Principal/Co-Investigators of the project. AIMIL Pharmaceuticals India Ltd is sponsoring about Rs 50 lakh for this novel research on Anti-Cancer Ayurvedic formulation.
The anticancer activity of herbal extract V2S2 has been studied and compared with Adriamycin, which is an established chemotherapeutic drug. The experimental procedure was performed as per National Cancer Institute (NCI) guidelines at ACTREC (Advanced Centre for Treatment, Research and Education in Cancer) TATA Memorial Cancer Centre, Mumbai.
The Ayurvedic drug code-named V2S2 is a Hydro-Alcoholic extract from 06 Ayurvedic herbomix. The significant anti-cancer activity of V2S2 was initially found at the lab scale which has been published in different national and international journals of repute.
Prof. Sanjeev Sharma appreciated this approach of collaborative research and expected very fruitful results from the defined protocol of the studies in the integrative methodology of AYUSH validation with modern parameters and complimented all stakeholders.
Speaking on the occasion, Dr Mohan Singh informed this milestone has been made possible today by the active support and guidance of Bhupinder Kumar IAS, Secretary to the Government Health & Medical Education Department. He hoped that this project will be a turning point in cancer treatment through Ayurveda and will encourage more research in the Ayush sector at the UT of J&K.
He further informed that an ethical committee for developing Research Methodologies in Ayurveda is being constituted for Govt Ayurvedic Hospital, Jammu. He stressed for evidence-based research in the Ayush sector and informed that Ayush has already stood the test of time and its acceptability is increasing day by day worldwide.
